Navigation Links
Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
Date:2/12/2013

Dallas, TX (PRWEB) February 12, 2013

The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the world’s leading healthcare companies.

  •     Trends in regenerative medicine and stem cells deals
  •     Deal terms analysis
  •     Partnering agreement structure
  •     Partnering contract documents
  •     Top deals by value
  •     Most active dealmakers
  •     Average deal terms for regenerative medicine and stem cells

The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multi component, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2008 including financial terms were available including over 550 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  •     What is actually granted by the agreement to the partner company?
  •     What exclusivity is granted?
  •     What are the precise rights granted or optioned?
  •     What is the payment structure for the deal?
  •     How are sales and payments audited?
  •     What is the deal term?
  •     How are the key terms of the agreement defined?
  •     How are IPRs handled and owned?
  •     Who is responsible for commercialization?
  •     Who is responsible for development, supply, and manufacture?
  •     How is confidentiality and publication managed?
  •     How are disputes to be resolved?
  •     Under what conditions can the deal are terminated?
  •     What happens when there is a change of ownership?
  •     What sublicensing and subcontracting provisions have been agreed?
  •     Which boilerplate clauses does the company insist upon?
  •     Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  •     Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of drug deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in regenerative medicine and stem cells deal making since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma, and most active of all bio pharma companies.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of regenerative medicine and stem cells deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of regenerative medicine and stem cells partnering deals signed and announced since 2009, where a contract document is available in the public domain.

In addition, a comprehensive appendix is provided organized by regenerative medicine and stem cells partnering company A-Z, deal type definitions and regenerative medicine and stem cells partnering agreements example. Each deal title links via Web link to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of regenerative medicine and stem cells technologies and products.

Buy your copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=219403 . Alternatively, you can ask question @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=219403 before making your final purchase decision.

Explore more reports on Biotechnology Market

About US:
ReportsnReports.com is an online market research reports library of 200,000+ in-depth studies of over 5000 micro markets.

Read the full story at http://www.prweb.com/releases/regenerative-medicine-and/stem-cells-deals-analysis/prweb10422074.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
2. The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee
3. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
4. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
5. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
6. Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives
7. ODT Forum Presents Regenerative Technologies
8. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. ALCAT Pioneer, Roger Deutsch, to Address "Food Allergies and Intolerances" at the Institute of Functional Medicine Conference in Tampa, February 8-10
11. Southwest Integrative Medicine Offers Free eBook "Do Your Hormones Need Balancing?"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb.10, 2016 ASAE is introducing a hybrid ... Companies (AMC) the option of joining or renewing through ... determined by staff size, every employee in any size ... and reap all available member benefits.   ... organizational membership options will allow organizations of any size ...
(Date:2/10/2016)... Texas (PRWEB) , ... February 10, 2016 , ... ... centers across three states, announced today the promotion of two long-standing principal investigators ... Chief of Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
(Date:2/9/2016)... LITTLE FALLS, N.J. , Feb. 9, 2016 ... ), a biotechnology company specializing in the development ... the health of damaged tissues and organs, recently ... milestones for the first quarter of 2016. ... Regenicin began the new 2015 fiscal year in ...
Breaking Biology Technology:
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the world-leading ... and publication industries, will provide the data management solution ... (NPSC). ... Phenotypic analysis measures the ... organisms, allowing comparisons between states such as health and ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):